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Available online 2 March 2017Long-term antiresorptives use has been linked to atypical subtrochanteric and diaphyseal femoral fractures
(AFF), the pathogenesis of which is still unknown. In the present case report we present the results of analysis
of bone chips froma 74-year old female patient that had been on alendronate, ibandronate and denosumab treat-
ment, and who sustained an atypical femoral fracture, by histology, quantitative backscattered electron imaging,
and Raman spectroscopic analysis.
The results indicate ongoing osteoclastic resorption, but also several abnormalities: 1) an altered arrangement of
osteons; 2) impaired mineralization; 3) the presence of pyrophosphate, which might contribute to the impaired
mineralization evident in the present case. Taken together, these changes may contribute to the focally reduced
bone strength of this patient.




Suppression of bone turnover has been amajor strategic approach in
the management of osteoporosis, using therapies such as estrogens,
bisphosphonates (BP), or RANK-L inhibitors. Nevertheless, prolonged
bone suppression has been hypothesized as the culprit in adverse occur-
rences such as atypical femoral fractures (AFF) (Shane et al., 2013), al-
though a direct cause-effect relationship has not been established to
date. The rarity of such side effects (b1/10,000) suggests, that other
mechanisms may play a contributing role (Alonso et al., 2015). To
date, altered bonematerial properties and increased mineralization ho-
mogeneity have been hypothesized to be the cause (Ettinger et al.,
2013). Recently a case report in JBMR described the occurrence of an
AFF in a woman with hypophosphatasia (a condition characterized by
accumulation of substrates of alkaline phosphatase such as pyrophos-
phate, phosphoethanolamine, and pyridoxal 5′phosphate) treated
with the bisphosphonates Alendronate and zoledronic acid over a peri-
od of 4 years (Sutton et al., 2012).
In the present study we analyzed bone chips obtained from the frac-
ture site during surgery from a 74 year old female patient that had beennc. This is an open access article undon bisphosphonates therapy (mainly alendronate) for more than seven
years, followed by treatment with two doses of denosumab, and who
sustained an AFF, by histology, quantitative backscattered electron im-
aging (qBEI) and Raman microspectroscopic (RS) analysis, to explore
potential differences in the composition of theAFF bone, including pyro-
phosphate, as detected by RS (Sutton et al., 2012; Cundy et al., 2015).
2. Materials & methods
The patientwas a 74 years-old female, whowent throughmenarche
at the age of 14 and menopause at 44 years. She had two children, with
accumulated breastfeeding for 17 months. She had no significant clini-
cal problems.
In 2006 (at age 67 yrs) she suffered a fracture of humeral diaphysis.
DXA assessment of bonemass revealed a LS-BMD T-score of−4.02 and
Femoral Neck T score−2.95. She startedweekly alendronate therapy in
2006. Due to upper GI complaints, she changed tomonthly ibandronate
regimen for a few months in 2008, before returning to weekly
alendronate treatment. In December 2012 her GP prescribed
denosumab, of which she received two doses. In November 2013, pre-
ceded by several weeks of prodromal pain, she suffered a diaphyseal
fracture of the right femur due to a fall (five and a half months after
the second dose of denosumab). The X-ray revealed a horizontaler the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.X-ray of the patient showing the horizontal fracture line and other characteristics of
AFF. The area from which the bone chips were collected is indicated by a white arrow.
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guidelines (Shane et al., 2013). At the time of fracture her lab values
were: S-25(OH)D 21.7 (ng/ml); S-PTH 57 pg/ml; S-osteocalcin b2
(below lower limit); CTX 0.15 (0.10–1.00). The fracture was treated
within 2 h of occurrence, with a long intramedullary nail and treatment
with teriparatide was initiated. Bone chips removed during surgery
were subsequently used for the present study (periosteal side of cortical
bone). Informed consent was obtained from the patient beforehand.
There were no comorbidities when the patient was admitted with the
AFF. The only value out of normal range was 25OHvitamin D
(21.5 ng/ml). Later on a mild hypercholesterolemia (treated with sim-
vastatin) and mild hypertension (no drug treatment) were detected.
The patient, after rehabilitation, is followed up regularly in our outpa-
tient clinic.2.1. Control bone
As control (CTRL), femoral midshaft bone from an 89 years old fe-
male (post-mortem, no sign of any skeletal disease) was used.Fig. 2. Lightmicroscopic images of histological sections from bone of the fracture site fromAFF p
with enlarged osteocyte lacunae and numerous resorption lacunae and osteoclasts; right: one2.2. Histology
The bone sample from the AFF site was fixed and dehydrated in eth-
anol, followed by propanol and xylene, followed by a three-step infiltra-
tion with methyl methacrylate. Dehydration and infiltration were
performed at 4 °C in a vacuum desiccator and polymerization at
−20 °C. The specimen was cut into 7 μm serial sections and dried over-
night. Sections were then de-plasticized and stained through the
Goldner modification of the Masson trichrome stain.
2.3. qBEI
qBEI analysis was performed on: 1) the bone sample from the AFF
site, which was used also for the histological examinations; 2) a trans-
versal 10 mm thick cross section of CTRL bone embedded in PMMA. In-
strumental and methodological details have been published elsewhere
(Cundy et al., 2015; Roschger et al., 2008; Roschger et al., 1995;
Roschger et al., 1998). Five variables were evaluated to characterize
the BMDD: CaMean, the weighted mean Ca-concentration of the bone
area; CaPeak, themode of Ca-concentration (the peak position of the his-
togram); CaWidth, the full width at half maximumof the distribution, de-
scribing the variation inmineralization density; CaLow, the percentage of
mineralized bone with a calcium concentration in the bottom 5% of the
reference cancellous BMDD (b17.68 wt% Ca); and CaHigh the portion of
bone areaswith a calciumconcentration higher than the 95th percentile
(N25.30 wt% Ca) of the reference cancellous BMDD (Roschger et al.,
2003). In addition to the control bone tissue, the qBEI of BMDD were
compared with previously published values from cortical bone of
transiliac biopsies samples from postmenopausal patients that were
on alendronate or risedronate therapy (CtRef) (Misof et al., 2010).
2.4. Raman spectroscopy (RS)
Raman microspectroscopic analyses were performed on the identi-
cal sample blocks (AFF bone sample and CTRL bone sample) used for
qBEI analysis after the carbon coatingwas removed by polishing. Instru-
mental and methodological details have been published elsewhere
(Cundy et al., 2015; Gamsjaeger et al., 2011a; Gamsjaeger et al., 2013;
Gamsjaeger et al., 2010; Gamsjaeger et al., 2014a, 2014b; Gamsjäger
et al., 2009; Hofstetter et al., 2012). In the bone blocks, 600 individual
measurements (each covering an area of ~1 × 1 μm) were obtained in
randomly selected areas of interstitial bone, and the following Raman
parameters calculated (Gamsjaeger et al., 2014b; Gamsjäger et al.,
2009; Gamsjaeger et al., 2011b; Morris andMandair, 2011): i) themin-
eral/matrix ratio (MM), ii) the relative proteoglycan content (PG), iii)
the maturity/crystallinity (MMC) of the mineral crystallites, and iv)
the relative content of two advanced glycation endproducts (AGEs),atient: Goldner trichrome stained bone sections, left: predominantly primarywoven bone
osteon like feature with osteoid (red).
Fig. 3. Section of bone chip at the fracture site of an AFF patient: A) and B) qBEI-image (overview and detail, respectively), circles indicate primary woven bone, arrows lamellar deposited
bone. C) Circular polarized light differential interference contrast (C-DIC) image of area in B (indicated by rectangular dashed frame); arrow - lamellar structure clearly visible, circle -
enlarged irregular shaped osteocyte lacunae. D) Control compact osteonal bone from femoral midshaft (age, sex matched).
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(Beattie et al., 2010; Beattie et al., 2011; Glenn et al., 2007; Pawlak et
al., 2008). Pyrophosphate (PP) presence and spatial quantification in
the bone tissue was determined using the Raman band around
360 cm−1 (Chen et al., 2009; Cheng et al., 2009; Fuerst et al., 2010), nor-
malized to mineral content (based on the v2PO4 band), by RS imaging
(210 × 130 μm areas) of open osteons.
In addition to the control bone tissue, the Raman results for mineral/
matrix, PG, andMMCwere compared with previously published values
from interstitial bone from postmenopausal patients that were on long
term (10 years) ALN therapy (ALN-L), with no AFF incidence (Hassler et
al., 2015).
3. Results
Histologic analysis revealed numerous osteoclasts on scalloped bone
surfaces. Moreover the remodeling areas were characterized by wid-
ened osteoid seams covered by flattened osteoblasts and mineralized
bone exhibited enlarged, irregular shaped osteocyte lacunae showing
osteocytic osteolysis (Fig. 2).Fig. 4. BMDD characteristics of the bone chips removed from the AFF site indicated that it
was shifted towards lower, more heterogeneous mineralization compared to CTRL. The
mean and mode calcium content (CaMean −12.3% and CaPeak −7.8%), were reduced and
heterogeneity of mineralization (CaWidth +46.8%), was elevated as well as the
percentage of bone with low mineralization (CaLow +409%) and the percentage of bone
with increased mineralization (CaHigh −81%) was reduced (Table 1). Moreover the AFF-
bone revealed a lower degree of mineralization compared to cortical bone of transiliac
bone biopsy samples from postmenopausal osteoporosis patients on alendronate or
risendronate therapy (CtRef) (Misof et al., 2010). On the other hand the BMDD of the
CTRL-bone was shifted to higher mineralization compared to the CtRef-bone (Table 1).Backscattered electron imaging of the bone tissue from fracture site
of the AFF patient revealed a scaffold of highlymineralized, porous bone
matrix with numerous enlarged osteocyte lacunae, on which lamellar
bone matrix was laid down (Fig. 3A, B, C) very different from normal
compact osteonal boneof CTRL (Fig. 3D). BMDD inAFF-bonewas shifted
towards lower, more heterogeneous mineralization compared to CTRL.
The mean and mode calcium content (CaMean −12.3% and CaPeak −
7.8%), were reduced and heterogeneity of mineralization (CaWidth +
46.8%), was elevated as well as the percentage of bone with lowminer-
alization (CaLow +409%) and the percentage of bone with increased
mineralization (CaHigh −81%) was reduced (Fig. 4, Table 1). Moreover
the AFF-bone revealed a lower degree of mineralization compared to a
cortical reference (CtRef) comprised of cortical bone of transiliac crest
bone biopsies sample from a cohort of women (n= 16)with postmen-
opausal osteoporosis on either alendronate or risendronate therapy. On
the other hand the BMDD of the CTRL-bone was distinctly shifted to
higher mineralization compared to the CtRef-bone (Fig. 4, Table 1). RS
analysis indicated that the MM of the bone tissue from the AFF patient
was lower compared to CTRL (Fig. 5a), while the PG content and MMC
valueswere higher in the AFF case (Fig. 5b and c, respectively). Both rel-
ative CML and PEN contents were elevated in the AFF case compared to
CTRL (Fig. 5d and e, respectively). RS analysis for the presence of pyro-
phosphate, revealed its presence above instrument detection limit
only in the AFF case (Fig. 6). No significant differences were evident be-
tween the AFF and the ALN-L in the mineral/matrix ratio and MMC
values, unlike the PG where the AFF had elevated ones (Fig. 5a–c).
4. Discussion
AFFs, although rare, have been identified as severe complications of
prolonged bone turnover suppression in osteoporotic patients on
antiresorptive therapies. No mechanism has been conclusively proven
yet for their occurrence, though alterations in the bonematerial proper-
ties have been proposed as a culprit. In the present study we analyzed
bone chips removed during surgery at the fracture site from a 74-yr
old patient that had sustained an AFF andwhohad been on ALN therapyTable 1
Corresponding values of BMDD parameters.
BMDD-parameter CtRef CTRL AFF Diff%
CaMean [wt% Ca] 22.26 ± 0.7172 24.19 21.22 −12.3
CaPeak [wt% Ca] 22.81 ± 0.7288 24.43 22.53 −7.8
CaWidth [wt% Ca] 3.710 ± 0.3136 2.95 4.33 +46.8
CaLow [%] 4.317 ± 1.452 2.05 10.45 +409.8
CaHigh [%] – 28.98 5.50 −81.0
CtRef = mean cortical BMDD parameters (mean ± SD, n = 16) from published values
(Misof et al., 2010); Diff% = percentage of difference between CTRL and AFF.
Fig. 5. Raman spectroscopic analysis outcomes: mineral/matrix (a), relative proteoglycan content (b), mineral maturity/crystallinity (c), CML (d), and pentosidine (e). The bone chip from
the AFF-sustaining patient (AFF) was compared against bone a site-, age-, and sex-matched bone from a healthy donor (CTRL), and postmenopausal osteoporosis patients treated with
long-term (10 years) alendronate therapy (ALN-L).
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a brief administration of denosumab. Distinct changes at the bone tissue
and material level were observed at this skeletal site, when compared
with site, age and sex matched healthy control bone.
4.1. Tissue level
The femoral bone chips examined in the present study exhibited an
abnormally high porosity and distinct deviations from a compactFig. 6.Results of the Raman imaging analysis of the bone chip from the patientwith the atypical
Raman image based on the height of the typical band for pyrophosphate (PP) ~360 cm−1 (norosteonal bone structure as found in normal femoral diaphysis, consis-
tent with previously published observations based on X-rays (Shane
et al., 2013; Shane et al., 2010), and scintigraphy (Shane et al., 2010)
considerations. qBEI and C-DIC images (circular polarized light differen-
tial interference contrast imaging) revealed a scaffold of highlymineral-
ized, porous bone matrix with enlarged osteocyte lacunae, on which
lamellar bone was laid down. The entire tissue was very different from
normal compact osteonal bone of CTRL. Histological analysis revealed
numerous osteoclasts on scalloped bone surfaces, widened osteoidfracture. A photomicrograph of the imaged area is shown on the right, while the calculated
malized to mineral content) is shown on the left.
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any osteoblasts were observed, suggesting that at the fracture site,
bone was continuously transformed from normal osteonal compact
bone to a highly porous one with disturbed osteonal arrangement,
potentially as a response to focally ongoing fatigue damage processes.
4.2. Material level
Compared to the CTRL-bone sample the AFF-bone showed a general
shift to lowermatrix mineralization. Three scenarios can be responsible
for this: 1) the average tissue age of the AFF bone is significantly youn-
ger than the CTRL due to an increased bone turnover rate; 2) the bone
matrix mineralization kinetics are altered; 3) a combination of 1 and
2. The lack of any osteoblastic activity in the AFF-bone suggests that
the secondhypothesis ismore plausible. It is also supported by the pres-
ence of pyrophosphate (mineralization inhibitor), which was detected
only in AFF. The strongly increased width of the BMDD-peak is likely
reflecting that two bone types are present in AFF-bone: the primary
woven bonewith a relative highmatrix mineralization and the lamellar
bone of lower mineral content. It is also noteworthy that the osteonal
CTRL-bone is distinctly higher mineralized than cancellous bone of a
normative reference data base (Roschger et al., 2003) most likely indi-
cating differences in average matrix mineralization density between
these skeletal sites (Fratzl-Zelman et al., 2009).
In contrast to qBEI, RS analysis was performed on single points with
focus directed towards the oldest tissue in the bone sample (interstitial
bone areas), with exception of the pyrophosphate measurements
where open osteons were also considered.
The MM of the AFF-bone was lower than CTRL-bone, in agreement
with the qBEI results. It was also similar to the ALN-L patients, suggest-
ing that the present AFF may not be necessarily attributed to the long
term antiresorptive therapy as far as this bone quality index is con-
cerned. PG (negative modulators of mineralization (Boskey et al.,
1997; Mochida et al., 2003; Mochida et al., 2009; Nielsen et al., 2003;
Bi et al., 2006; Xu et al., 1998; Sauren et al., 1992; Thompson et al.,
2011; Gualeni et al., 2013; Ohtsuki et al., 1995)) content of the AFF
case was higher compared to either CTRL or ALN-L, possibly contribut-
ing to the lower mineralization measured in the AFF case. The MMC
(Fratzl et al., 2004; Donnelly et al., 2012a) of the AFF case was similar
to the CTRL and ALN-L, suggesting that it may not be contributing to
the AFF occurrence, and also argues against the contribution of active
fracture repair mechanisms (Ouyang et al., 2004) as would be expected
given that the patient was operated within 2 h of fracture occurrence.
On the other hand, the relative CML and PEN contentwas elevated in
the AFF case compared to CTRL, potentially contributing to the fragility
fracture as AGEs accumulation is believed to be detrimental to bone
strength (Karim et al., 2013).
A recent report described the development of an AFF in a patient
with hypophosphatasia being treated with zoledronic acid (Sutton et
al., 2012). Inorganic pyrophosphate is a primary antagonistic regulator
of extracellular matrix mineralization (Zhou et al., 2012), through its
competition against inorganic phosphate in the promotion of hydroxy-
apatite deposition (Moochhala et al., 2008; Harmey et al., 2004; Clarke,
2008; Anderson, 2003). In the present study we explored for its pres-
ence in areas of open osteons, by RS imaging analysis. The only speci-
men that exhibited detectable pyrophosphate levels by RS was the
AFF one. The lack of PP detection in all other groups may be due to the
fact that in healthy bone, PP levels are well below 1% (Perkins and
Walker, 1958).
A recent publication, reported on the cortical and trabecular bone
tissue properties and compositional heterogeneity near fragility fracture
sites of patients that were receiving either BP or another osteoporosis
therapy. Among the BP-receiving patients sustaining fragility fractures,
6 had AFF, 5 of which were on ALN and one on ibandronate therapy
(Donnelly et al., 2012b). The values for MM in the AFF subgroup were
no different compared to the non-AFF fragility fracture sub-group,unlike the present results. Moreover, the mineralization heterogeneity
was significantly reduced in the AFF sub-group, unlike the present re-
sults. However, MMC in the AFF subgroup was no different compared
to the non-AFF fragility fracture sub-group, in agreement with the re-
sults of the present study. A possible reason for this discrepancy could
be that in the previous study (Donnelly et al., 2012b), bone close to
the fracture site was analyzed, while in the present one a bone chip
from the actual fracture site was utilized, and as per ASBMR definition,
AFF is a focal weakness in bone thus analyzing bone from neighboring
sites may not be completely representative of the material properties
of an AFF site. Also in the already published study (Donnelly et al.,
2012b), all the analyzed patients were on antiresorptive therapy,
whereas in the present case the control tissue was from a necropsy
specimen not treated with any antiresorptives. On the other hand, it
should be kept in mind that the mineral/matrix and MMC values as de-
termined by RS were not different from the ones calculated in bone tis-
sue from patients on long-termALN therapy andwho did not suffer any
AFF, suggesting that antiresorptive therapy may not be reason for the
described discrepancies.
A unique finding of the present study is the presence of PP in the ex-
amined tissue at the fracture site of the AFF, which coupled to the ele-
vated PG values may be contributing to the lower mineral content and
delayed mineralization of bone matrix.
A limitation of the present study is that the control tissue we used
was from a necropsy specimen that was 15 years older than the AFF pa-
tient, and was deemed as healthy bone, as we do not have access to
bone tissue from a better age-matched, treatment-naïve postmeno-
pausal osteoporosis patient without any AFF incidence. On the other
hand, for the RS analyses, we compare the properties of the present
AFF bone tissue with those obtained in postmenopausal osteoporosis
patients who had been treated long term with antiresorptive therapy
without sustaining AFF. Moreover, for the qBEI analysis, we compared
the bone matrix mineralization of AFF bone with cortical bone of
transiliac bone biopsy samples from postmenopausal osteoporosis
patients on alendronate or risendronate therapy.
In conclusion, bone chips removed from the fracture site of an AFF
case showed ongoing osteoclastic resorption despite antiresorptive
treatment, an impaired arrangement of osteons, increased heterogene-
ity in mineralization, elevated proteoglycan, CML, and PEN content, and
PP accumulation. Taken together, these changes may contribute to the
focally reduced bone strength at the site of AFF in the present case.
The observationsmade are compatiblewith the assumption of an ongo-
ing history of focal fatigue damage coupled to a form of repair response
at the fracture site.
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